^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    adrixetinib (Q702)

    i
    Other names: Q702, Q 702, Q-702
    Associations

    News

    Trials
    Company:
    Qurient
    Drug class:
    AXL inhibitor, CSF-1R inhibitor, MERTK inhibitor
    Related drugs:
    Associations

    News

    Trials
    25d
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, Qurient Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    adrixetinib (Q702)
    7ms
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    10ms
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Qurient Co., Ltd. | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • adrixetinib (Q702)
    12ms
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=78, Recruiting, Qurient Co., Ltd. | Trial completion date: Nov 2023 --> Feb 2025 | Trial primary completion date: Jul 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    adrixetinib (Q702)
    almost2years
    Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors (AACR 2023)
    Up to 240 mg, Q702 has demonstrated the intended pharmacologic activity with acceptable safety profile. In biomarker analysis, immune modulation activity is exerted by Axl/Mer/CSF1R inhibition. Further assessment of pharmacokinetics, pharmacodynamics, safety and antitumor activity will be performed at the expansion phase at the RP2D in patients with selected advanced tumors.
    Clinical • P1 data • PK/PD data • Metastases
    |
    CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase)
    |
    adrixetinib (Q702)
    2years
    A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment. (PubMed, Cancers (Basel))
    Q702 induced antitumor activity in syngeneic tumor mouse models by: remodeling the TME toward immune stimulation; expanding M1 macrophage and CD8 T cell populations and decreasing M2 macrophage and MDSC populations in the TME; and increasing MHC class I and E-cadherin expression in tumor cells. Thus, Q702 may have great potential to broaden the coverage of populations benefiting from ICB-based immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase) • CDH1 (Cadherin 1) • CSF1R (Colony stimulating factor 1 receptor)
    |
    CDH1 expression
    |
    adrixetinib (Q702)